Last update 20 Mar 2025

BYON-4413

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Target
CD123 x DNA
Action
modulators, inhibitors
Mechanism
CD123 modulators(Interleukin-3 receptor subunit alpha modulators), DNA inhibitors(DNA inhibitors)
Therapeutic Areas
NeoplasmsHemic and Lymphatic Diseases
Active Indication
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Inactive Indication-
Originator Organization
Byondis BVByondis BV
Active Organization
Byondis BVByondis BV
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC11H22N4O4
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N
CAS Registry159858-33-0
View All Structures (2)
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with BYON-4413
NCT06359002
/ RecruitingPhase 1
A First-in-human Dose Escalation and Expansion Trial With the Antibody-drug Conjugate BYON4413 to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms.
100 Clinical Results associated with BYON-4413
Login to view more data
100 Translational Medicine associated with BYON-4413
Login to view more data
100 Patents (Medical) associated with BYON-4413
Login to view more data
100 Deals associated with BYON-4413
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 1
Netherlands
Byondis BVByondis BV
25 Jun 2024
Acute Myeloid LeukemiaPhase 1
Spain
Byondis BVByondis BV
25 Jun 2024
Acute Myeloid LeukemiaPhase 1
Belgium
Byondis BVByondis BV
25 Jun 2024
Myelodysplastic SyndromesPhase 1
Spain
Byondis BVByondis BV
25 Jun 2024
Myelodysplastic SyndromesPhase 1
Belgium
Byondis BVByondis BV
25 Jun 2024
Myelodysplastic SyndromesPhase 1
Netherlands
Byondis BVByondis BV
25 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free